why choose us

First received: December 23, 2022

Clinical Trial: A Clinical Trial of the Safety and Anti-Tumor Activity of AB-201 in Subjects With Advanced HER2+ Solid Tumors

Study Status: NOT_YET_RECRUITING

Recruit Status: NOT_YET_RECRUITING

Condition: Breast Cancer

Study Type: INTERVENTIONAL


Official Title: A Multicenter, Open-label, Phase 1/2 Clinical Trial to Evaluate the Safety and Anti-Tumor Activity of AB-201 in Subjects With Advanced HER2+ Solid Tumors

Brief Summary: This clinical trial will enroll subjects with HER2+ solid tumors and is conducted in two phases.The primary objective of Phase 1 is to determine the safety and tolerability of AB-201 in subjects with advanced HER2+ solid tumors.The primary objective of Phase 2 is to evaluate the efficacy of AB-201.Subjects will receive up to 3 doses of AB-201, followed by scheduled assessments of overall health and tumor response.

Read more